GenSci128 Receives Orphan Drug Designation for Pancreatic Cancer Treatment
Changchun High-Tech announced that its subsidiary, Changchun GeneScience Pharmaceuticals Co., Ltd., has received notification from the U.S. Food and Drug Administration granting orphan drug designation to GenSci128 for the treatment of pancreatic cancer. According to Jin10, this designation is a significant step for the company in advancing its efforts to address this challenging disease. The orphan drug status is expected to provide certain benefits, including market exclusivity and potential tax credits, which could aid in the development and commercialization of GenSci128.
Source: CoinLive The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments